SEC Form S-8 filed by Astria Therapeutics Inc.
As filed with the Securities and Exchange Commission on August 12, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Astria Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 26-3687168 | |||
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
22 Boston Wharf Road, 10th Floor Boston, Massachusetts |
02210 |
|||
(Address of Principal Executive Offices) | (Zip Code) |
Second Amended and Restated 2015 Stock Incentive Plan
2015 Employee Stock Purchase Plan
2022 Inducement Stock Incentive Plan, as amended
(Full Title of the Plan)
Benjamin Harshbarger
Chief Legal Officer
22 Boston Wharf Road, 10th Floor
Boston, Massachusetts 02210
(Name and Address of Agent For Service)
(617) 349-1971
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ¨ | Accelerated filer | ¨ |
Non-accelerated filer | x | Smaller reporting company | x |
Emerging growth company | ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement on Form S-8, relating to the Second Amended and Restated 2015 Stock Incentive Plan, the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan, as amended, of Astria Therapeutics, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective.
Accordingly, this Registration Statement incorporates by reference the contents of:
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. | Exhibits. |
The following exhibits are incorporated herein by reference:
EXHIBIT INDEX
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Boston, Commonwealth of Massachusetts, on this 12th day of August, 2024.
ASTRIA THERAPEUTICS, INC. | ||
By: | /s/ Jill C. Milne | |
Jill C. Milne | ||
President and Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Astria Therapeutics, Inc., hereby severally constitute and appoint Jill C. Milne, Benjamin Harshbarger and Noah C. Clauser, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Astria Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Jill C. Milne |
President and Chief Executive Officer and Director (Principal Executive Officer) |
August 12, 2024 | ||
Jill C. Milne | ||||
/s/ Noah Clauser | Chief Financial Officer | August 12, 2024 | ||
Noah Clauser | (Principal Financial Officer and Principal Accounting Officer) | |||
/s/ Kenneth Bate | Chairman of the Board of Directors | August 12, 2024 | ||
Kenneth Bate | ||||
/s/ Sunil Agarwal | Director | August 12, 2024 | ||
Sunil Agarwal | ||||
/s/ Joanne Beck | Director | August 12, 2024 | ||
Joanne Beck | ||||
/s/ Frederick P. Callori | Director | August 12, 2024 | ||
Frederick P. Callori | ||||
/s/ Hugh Cole | Director | August 12, 2024 | ||
Hugh Cole | ||||
/s/ Michael Kishbauch | Director | August 12, 2024 | ||
Michael Kishbauch | ||||
/s/ Gregg Lapointe | Director | August 12, 2024 | ||
Gregg Lapointe | ||||
/s/ Jonathan Violin | Director | August 12, 2024 | ||
Jonathan Violin |